
RealRate

PHARMACEUTICAL 2020

INTERCEPT PHARMACEUTICALS INC.



Rank 184 of 362



RealRate

PHARMACEUTICAL 2020

INTERCEPT PHARMACEUTICALS INC.



Rank 184 of 362

The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 78% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -184%, being 119% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	721,315
Cost of Goods Sold	4,212
Intangible Assets	0
Liabilities, Current	162,005
Liabilities, Non-Current	541,325
Other Assets	28,369
Other Compr. Net Income	1,122
Other Expenses	0
Other Liabilities	0
Other Net Income	-32,254
Property and Equipment	5,202
Research and Development	242,799
Revenues	252,002
Selling, General and Administrative Expense	317,418

Output Variable	Value in 1000 USD
Assets	754,886
Liabilities	703,330
Expenses	564,429
Stockholders Equity	51,556
Net Income	-344,681
Comprehensive Net Income	-344,120
Economic Capital Ratio	-184%